Company Profile

Avior Inc
Profile last edited on: 5/6/20      CAGE: 7UKR6      UEI: TXPKU9NECMH3

Business Identifier: Cures for neurology patients: disease condition and associated complications
Year Founded
2017
First Award
2019
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

701 West Main Street Suite 200
Durham, NC 27701
   (919) 200-6033
   admin@aviorx.com
   www.aviorx.com
Location: Single
Congr. District: 02
County: Durham

Public Profile

Avior is a clinical stage, pharmaceutical company developing drugs for distressed neurological conditions. The firm's disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – positions the firm to develop products that bring value both in terms of efficacy and in safety. Avior's lead product – AV104 – is designed to address treatment of Prurigo Nodularis and chronic kidney disease associated pruritus. In 2019, in response to the US Opioid crisis, and with NIH support, principals of the firm added a second product – AV103 – designed to create a medical counter measure (MCM) for the reversal of opioid induced respiratory

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Key People / Management

  Niraj Vasisht -- CEO

  Michael K Taylor -- Vice President Formulation and Process Development

  Ramesh C Vasishth

Company News

There are no news available.